Comgest Global Investors’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-10,147
| Closed | -$713K | – | 61 |
|
|
2024
Q3 | $713K | Sell |
10,147
-142,630
| -93% | -$11.9M | 0.01% | 60 |
|
|
2024
Q2 | $12.6M | Sell |
152,777
-59,687
| -28% | -$4.97M | 0.17% | 41 |
|
|
2024
Q1 | $18.6M | Buy |
212,464
+13,143
| +7% | +$1.18M | 0.26% | 37 |
|
|
2023
Q4 | $19.2M | Buy |
199,321
+22,313
| +13% | +$1.97M | 0.29% | 35 |
|
|
2023
Q3 | $15.7M | Buy |
177,008
+33,401
| +23% | +$2.97M | 0.27% | 35 |
|
|
2023
Q2 | $12.4M | Buy |
143,607
+22,273
| +18% | +$2.1M | 0.21% | 41 |
|
|
2023
Q1 | $11.8M | Sell |
121,334
-15,574
| -11% | -$1.61M | 0.22% | 38 |
|
|
2022
Q4 | $14.2M | Buy |
136,908
+10,493
| +8% | +$985K | 0.31% | 36 |
|
|
2022
Q3 | $10.7M | Buy |
126,415
+6,600
| +6% | +$588K | 0.24% | 39 |
|
|
2022
Q2 | $9.93M | Buy |
119,815
+13,203
| +12% | +$1.05M | 0.2% | 42 |
|
|
2022
Q1 | $8.22M | Buy |
106,612
+2,218
| +2% | +$186K | 0.13% | 44 |
|
|
2021
Q4 | $9.22M | Sell |
104,394
-2,751
| -3% | -$227K | 0.12% | 43 |
|
|
2021
Q3 | $8.28M | Buy |
107,145
+15,529
| +17% | +$1.23M | 0.11% | 44 |
|
|
2021
Q2 | $7.64M | Buy |
91,616
+1,400
| +2% | +$111K | 0.1% | 43 |
|
|
2021
Q1 | $6.81M | Sell |
90,216
-4,000
| -4% | -$327K | 0.1% | 39 |
|
|
2020
Q4 | $8.26M | Sell |
94,216
-1,000
| -1% | -$79.3K | 0.15% | 36 |
|
|
2020
Q3 | $7.24M | Buy |
95,216
+13,500
| +17% | +$1.37M | 0.11% | 38 |
|
|
2020
Q2 | $10.1M | Sell |
81,716
-2,200
| -3% | -$219K | 0.17% | 32 |
|
|
2020
Q1 | $7.09M | Sell |
83,916
-3,378
| -4% | -$291K | 0.14% | 34 |
|
|
2019
Q4 | $7.38M | Buy |
87,294
+16,294
| +23% | +$1.23M | 0.13% | 34 |
|
|
2019
Q3 | $4.79M | Buy |
71,000
+13,200
| +23% | +$1.02M | 0.1% | 39 |
|
|
2019
Q2 | $4.95M | Buy |
57,800
+3,600
| +7% | +$308K | 0.11% | 39 |
|
|
2019
Q1 | $4.81M | Buy |
54,200
+12,000
| +28% | +$1.11M | 0.11% | 38 |
|
|
2018
Q4 | $3.59M | Buy |
42,200
+7,600
| +22% | +$723K | 0.09% | 41 |
|
|
2018
Q3 | $3.35M | Buy |
34,600
+4,600
| +15% | +$459K | 0.08% | 45 |
|
|
2018
Q2 | $2.83M | Hold |
30,000
| – | – | 0.06% | 48 |
|
|
2018
Q1 | $2.43M | Hold |
30,000
| – | – | 0.05% | 48 |
|
|
2017
Q4 | $2.67M | Buy |
30,000
+4,500
| +18% | +$391K | 0.06% | 50 |
|
|
2017
Q3 | $2.37M | Buy |
25,500
+1,500
| +6% | +$133K | 0.06% | 50 |
|
|
2017
Q2 | $2.18M | Buy |
24,000
+7,900
| +49% | +$719K | 0.05% | 49 |
|
|
2017
Q1 | $1.41M | Buy |
+16,100
| New | +$1.43M | 0.04% | 50 |
|
|
2015
Q2 | – | Sell |
-5,000
| Closed | -$623K | – | 46 |
|
|
2015
Q1 | $623K | Sell |
5,000
-11,000
| -69% | -$1.17M | 0.02% | 47 |
|
|
2014
Q4 | $1.45M | Buy |
+16,000
| New | +$1.33M | 0.04% | 40 |
|
Other funds holding BMRN
EIM
Comgest Global Investors's BMRN Position: Q4 2024 in Review
Comgest Global Investors sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2024, closing a stake of 10,147 shares — an estimated $713K sold.
Comgest Global Investors first reported a position in BMRN in Q4 2014 and held it in 33 quarters. The position peaked at $19.2M in Q4 2023. 543 funds tracked by Wall St. Rank hold BMRN as of Q4 2024.
- Comgest Global Investors reported no remaining BioMarin Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
- Comgest Global Investors sold 10,147 BioMarin Pharmaceuticals shares in Q4 2024, an estimated $713K.
- Comgest Global Investors first reported a position in BioMarin Pharmaceuticals in Q4 2014 and held it in 33 quarters.
- Comgest Global Investors's BioMarin Pharmaceuticals position peaked at $19.2M in Q4 2023.
- 543 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2024.
Based on Comgest Global Investors's 13F filing for Q4 2024, filed 13 Feb 2025.